Benitec Biopharma says FDA requested more data on single-arm pivotal study of BB-301 in oculopharyngeal muscular dystrophy

Benitec Biopharma said the FDA requested additional data on a single-arm pivotal study of BB-301 for oculopharyngeal muscular dystrophy, and the company expects a final study design in Q1 2027.

Detected & updated continuously · Source: Nebula